2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Report calls for international collaboration and greater funding to drive antibiotic innovation as top priorities for countries.

New York, NEW YORK (February 15, 2024) – Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index. The 2021 Index examined over 100 metrics to evaluate and rank countries’ performance against AMR and establish benchmarks for policy action and leadership.

Each year, nearly 5 million deaths are associated with AMR, with disproportionate impact on low-and middle-income countries. Without the creation of innovative and novel antimicrobials, growing resistance to our existing drugs threatens our ability to perform even routine medical care. AMR is a significant barrier to health system sustainability and public health, including healthy aging. It is also an economic challenge – without correcting course on AMR, the World Bank estimates that AMR could cost the global economy as much as $3.4 trillion USD annually by 2023.

The 2024 Progress Report assessed the same eleven countries as the 2021 Index: Brazil, Canada, China, France, Germany, India, Italy, Japan, South Korea, the United Kingdom (UK), and the United States (US). The UK maintained its position as the global leader in the fight against AMR, and many of the countries showed promising progress in many areas, but there is still greater action and targeted investment needed across all countries evaluated, particularly to revive the floundering pipeline of novel antibiotics.

“AMR is no longer just a public health threat – it is already here,” said Michael Hodin, CEO of GCOA. “It’s imperative that global leaders leverage their power – both separately and collaboratively – to commit and implement concrete actions in the face of growing drug resistance. Without such action, we risk losing antibiotics, and with them, our ability to enjoy the longevity that we do currently. We hope that HLM in September will provide a forum to spur action and enable much-needed collaboration between countries.”

Key Takeaways of the 2024 AMR Preparedness Index Progress Report:

  • Many countries have updated or created new national strategies on AMR.
  • The antimicrobial market and antimicrobial innovation continues to be a major challenge around the world.
  • The COVID-19 pandemic stymied progress on antimicrobial stewardship in several countries.
  • The state of antimicrobial access has seen very little change from 2021, with few new approvals and little difference in affordability metrics across countries.
  • Environmental initiatives saw modest progress in many countries.

Across indicators, more needs to be done to put a firm halt to the spread of AMR, including the following points:

  • Governments should invest further in national action plans, making bold investments in AMR countermeasures as a key element of health system resiliency.
  • Governments should implement robust push and pull incentives to revitalize antibiotic innovation.
  • Governments should make the availability of novel antimicrobials a national priority, ensuring access and affordability.
  • Governments should invest further in infectious disease training for medical professionals and better incentivize specialization in infectious disease medicine.
  • Governments should work to further strengthen and connect resistance and antimicrobial consumption surveillance systems, including by investing in diagnostics infrastructure.
  • Governments should further support data collection on AMR in the environment.

These key actions and more are detailed in the comprehensive main text of the 2024 AMR Preparedness Index Progress Report. The urgency of these findings underscores the collective responsibility to address AMR promptly and effectively.

Featured during today’s launch of the Progress Report were:

  • André Luiz de Abreu, Ministry of Health, Brazil
  • Neil J. Clancy, AMR Committee, Infectious Diseases Society of America
  • Dame Sally Davies, UK Special Envoy on AMR
  • Michael W. Hodin, Global Coalition on Aging
  • Andrew Jack, Financial Times
  • Matt McEnany, GCOA
  • Dani Peters, Canadian Antimicrobial Innovation Coalition, Canada
  • Maria Jose Ruiz Alvarez, Italian National Institute of Health (ISS)
  • John Rex, AMR Solutions
  • Luka Srot, IFPMA

The development of the 2024 AMR Preparedness Index Progress Report was supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

For media inquiries, please contact:
Danny O’Keefe
[email protected]
(917) 565-3001

About the Global Coalition on Aging

The Global Coalition on Aging (GCOA) aims to reshape how global leaders approach and prepare for the 21st century’s profound shift in population aging. GCOA uniquely brings together global corporations across industry sectors with common strategic interests in aging populations, a comprehensive and systemic understanding of aging, and an optimistic view of its impact. Through research, public policy analysis, advocacy, and strategic communications, GCOA is advancing innovative solutions and working to ensure global aging is a path to health, productivity, and economic growth. For more information, visit www.globalcoalitiononaging.com.

About the Infectious Diseases Society of America:

IDSA is a leader on issues of importance to ID professionals, including education and training, policy and advocacy, setting guidelines for patient care, and developing resources for clinical practice. It remains at the forefront of global health issues such as COVID-19, antimicrobial resistance and HIV/AIDS. Housed within IDSA is the HIV Medicine Association, (HIVMA) which represents medical providers and researchers working on the front lines of HIV. More than 12,000 IDSA and HIVMA members work across the United States and in nearly 100 other countries on six different continents.  For more information visit www.idsociety.org. Follow IDSA on  Facebook and Twitter.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.